Advanced search×

Cost of evaluation of patients with pituitary incidentaloma.

Benjamin R Randall, Kristin L Kraus, Marie F Simard, and William T Couldwell

Pituitary 13(4):383-4 (2010) PMID 20628820

DOI: 10.1007/s11102-010-0241-8
Version: za2963e q8za7 q8zb3 q8zc5 q8zd8 q8ze8 q8zfd q8zg8
Buy PDF

Similar articles you may find interesting…

  1. Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma.
    M Alberiche Ruano, M Boronat Cortés, ... F J Novoa Mogollón

    Pituitary 13(4):380-2 (2010) PMID 20652638

    Buy PDF
  2. [Mirtazapine-associated hepatotoxicity].
    María Soledad Rodriguez-Pecci, Javier de la Fuente-Aguado, ... Francisco J Fernandez-Fernandez

    Med Clin (Barc) 135(13):625-6 (2010) PMID 19822332

    Buy PDF
  3. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes.
    R P Hoogma and D Schumicki

    Horm Metab Res 38(6):429-33 (2006) PMID 16823727

    This twelve-week, European, multicenter, controlled, open-label, randomized (1 : 1), parallel-group trial compared the safety of insulin glulisine with insulin as part used in continuous subcutaneous insulin infusion. Patients with type 1 diabetes (n=59) and continuous subcutaneous i...
    Buy PDF